Design and synthesis of 3,4-dihydro-2H-benzo[h]chromene derivatives as potential NF-κB inhibitors

被引:30
作者
Choi, Minho [1 ]
Hwang, Young-Sik [1 ]
Kumar, Arepalli Sateesh [1 ]
Jo, Hyeju [1 ]
Jeong, Yeongeun [1 ]
Oh, Yunju [1 ]
Lee, Joonkwang [1 ]
Yun, Jieun [2 ]
Kim, Youngsoo [1 ]
Han, Sang-bae [1 ]
Jung, Jae-Kyung [1 ]
Cho, Jungsook [3 ]
Lee, Heesoon [1 ]
机构
[1] Chungbuk Natl Univ, Dept Pharm, Chungbuk 361763, South Korea
[2] Korea Res Inst Biosci & Biotechnol, Ochang 363883, South Korea
[3] Dongguk Univ, Coll Pharm, Goyang 410773, South Korea
基金
新加坡国家研究基金会;
关键词
NF-kappa B inhibitors; Cytotoxic activity; N-Lambda yl-3,4-dihydro-2H-benzo[h]chromene-2-caboxamide; derivatives; CONSTITUTIVE ACTIVATION; CELLS; PATHWAYS; CANCER;
D O I
10.1016/j.bmcl.2014.04.053
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A novel class of NF-kappa B inhibitors were designed and synthesized based on KL-1156 (6-hydroxy-7-methoxychroman-2-carboxylic acid phenyl amide) which is unambiguously considered to be a promising inhibitor for the translocation step of NF-kappa B. Especially in this study we focused on the modifying the chroman moiety of KL-1156 into four parts for exploring the SAR studies linked with physical properties of substituents resulted the development of novel 1a-k, 2a-f, 3a-d and 4a-d derivatives of 3,4-dihydro-2H-benzo[h] chromene. From the SAR studies we were very delightfully identified that several new N-aryl-3,4-dihydro-2H-benzo[h] chromene-2-carboxamide derivatives (1a-k) exhibited good inhibitory activity and anti-proliferative activity than parent lead compound KL-1156, among them 1i exhibited outstanding inhibitory effect on LPS-induced NF-kappa B transcriptional activity and anti-proliferative activity on NCI-H23 lung cancer cell lines than KL-1156. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2404 / 2407
页数:4
相关论文
共 27 条
[1]  
Bharat B. A., 2004, CANCER CELL, V6, P203
[2]   The NF-κB regulatory network [J].
Brasier, Allan R. .
CARDIOVASCULAR TOXICOLOGY, 2006, 6 (02) :111-130
[3]  
Feinman R, 1999, BLOOD, V93, P3044
[4]   Introduction to NF-κB:: players, pathways, perspectives [J].
Gilmore, T. D. .
ONCOGENE, 2006, 25 (51) :6680-6684
[5]   The Rel/NF-κB signal transduction pathway:: introduction [J].
Gilmore, TD .
ONCOGENE, 1999, 18 (49) :6842-6844
[6]   Leukemia stem cells and constitutive activation of NF-κB [J].
Griffin, JD .
BLOOD, 2001, 98 (08) :2291-2291
[7]   Evidence that reactive oxygen species do not mediate NF-κB activation [J].
Hayakawa, M ;
Miyashita, H ;
Sakamoto, I ;
Kitagawa, M ;
Tanaka, H ;
Yasuda, H ;
Karin, M ;
Kikugawa, K .
EMBO JOURNAL, 2003, 22 (13) :3356-3366
[8]   Signaling to NF-κB [J].
Hayden, MS ;
Ghosh, S .
GENES & DEVELOPMENT, 2004, 18 (18) :2195-2224
[9]   Inhibitory mechanism of chroman compound on LPS-induced nitric oxide production and nuclear factor-κB activation [J].
Kim, BH ;
Reddy, AM ;
Lee, KH ;
Chung, EY ;
Cho, SM ;
Lee, H ;
Min, KR ;
Kim, Y .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 325 (01) :223-228
[10]   Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells [J].
Kordes, U ;
Krappmann, D ;
Heissmeyer, V ;
Ludwig, WD ;
Scheidereit, C .
LEUKEMIA, 2000, 14 (03) :399-402